Targeted Therapy for Sleep Apnoea



Professor Danny Eckert, Professor Lynne Bilston, Dr Michelle Donegan, Dr Alan Chiang, Dr Jayne Carberry, Benjamin Tong, Carolin Tran, Andrea Ricciardiello, Jade Yeung

The study aims to investigate how targeted therapy using a mandibular advancement device works to open the upper airway in sleep apnea.

To take part in this study, you must;

  • Have been diagnosed with sleep apnoea and are otherwise healthy
  • Be aged over 18
  • Not be pregnant or breastfeeding

If you take part in the study you would:

  • Be referred into the study by a sleep specialist
  • Visit NeuRA in Randwick for a minimum of 2 dental appointments and 3 overnight studies
  • We will apply a range of stick on recording devices
  • Participate in awake breathing tests
  • Be monitored overnight
  • Some invasive nose, tongue and throat sensors will be used

Please contact: 

Andrea or Carolin

9399 1886

See what’s going on at NeuRA


LEAD!- Leveraging Evidence into Action on Dementia

Currently, there is no effective treatment for dementia, highlighting the urgent need to preventing more cases through evidence-based strategies for risk reduction. As there is an overlap between the risk factors for dementia and other preventable non-communicable diseases including stroke, diabetes, and heart disease, it is important to build upon proven risk-reduction strategies. What is LEAD? LEAD! is a project funded by the NHMRC Boosting Dementia Research Grant led by Professor Kaarin Anstey. It involves an international collaboration between leading academics, clinicians, consumers, and community members. Organisations involved include the Department of Health, WHO, Dementia Australia, Alzheimer’s Disease International, Diabetes Australia, and Heart Foundation. The project aims to translate dementia research and implement evidence-based strategies for dementia risk reduction to individuals, communities, and healthcare centres. Three workstreams The project has three concurrent workstreams over five years: Development, Implementation, and Evaluation and adoption. The Development stream, led by Professor Kaarin Anstey and Associate Professor Peters, focuses on building a new tool for predicting dementia and other non-communicable diseases including stroke, diabetes or myocardial infarction. The tool will be available to the public, researchers and clinicians. It will save clinical assessment time, accurately predict multiple outcomes and will be more acceptable in comparison to using individual tools for each disease outcome. The Implementation stream led by Professor Nicola Lautenschalger’s team at the University of Melbourne, will develop strategies to support the implementation of dementia risk reduction evidence by engaging with consumers, clinicians, policy makers, and the public. The stream will develop strategies for incorporating the new risk assessment tool into various technological platforms (e.g., websites or apps). The Evaluation and adoption stream, led by Professor Anstey and in collaboration with Professor Louisa Jorm and Dr Heidi Welberry at UNSW, focuses on measuring trajectories of Australian’s national risk factor profiles for multiple chronic diseases. Collaboration with key stakeholders including the WHO will help build an evaluation framework and methodology for implementing evidence on dementia risk reduction based on WHO guidelines at national level and in the global context.